Jakarta - National TB Vaccine Researcher Prof. DR. dr. Erlina Burhan, Sp.P(K), revealed the progress of the M72/AS01E Tuberculosis (TB) vaccine as a vaccine currently being researched by Indonesia to protect adolescents and adults from TB disease.
Doctor Erlina in an online meeting with the media attended in Jakarta, Monday, said that Indonesia is currently entering the phase three clinical trial stage for the M72 TB vaccine after previously successfully passing the phase 2B clinical trial process which produced promising results with a vaccine efficacy value of 50 percent.
"We are currently conducting phase 3 clinical trials. And hopefully the recruitment will be completed in early April. Then we just have to follow the participants for the next three years, so that in 2028 there will be results and hopefully it can be produced in parallel and by the end of 2028 the production will be there," said Dr. Erlina.
In her presentation, Dr. Erlina said that the M72/AS01E TB vaccine has the potential to be one way to reduce cases of Tuberculosis in adults and adolescents after the last time a similar vaccine, namely the BCG vaccine, was discovered but was proven to only be able to protect the infant age group.